SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
FRA:1SXP - Deutsche Boerse Ag - DE000A3ENQ51 - Common Stock - Currency: EUR
Taking everything into account, 1SXP scores 5 out of 10 in our fundamental rating. 1SXP was compared to 16 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
1SXP had a positive operating cash flow in the past year.
In the past 5 years 1SXP has always been profitable.
1SXP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1SXP's Return On Assets of 9.93% is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
1SXP has a Return On Equity of 17.64%. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
1SXP has a Return On Invested Capital of 14.25%. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 6.91%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.93% | ||
| ROE | 17.64% | ||
| ROIC | 14.25% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP's Profit Margin of 15.17% is amongst the best of the industry. 1SXP outperforms 87.50% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
With an excellent Operating Margin value of 18.95%, 1SXP belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
1SXP's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 32.90%, 1SXP perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 15.17% | ||
| GM | 32.9% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
1SXP has a worse debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.33, which is an excellent value as it means it would take 1SXP, only 1.33 years of fcf income to pay off all of its debts.
1SXP has a better Debt to FCF ratio (1.33) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that 1SXP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.10, 1SXP belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.33 | ||
| Altman-Z | N/A |
ROIC/WACC1.84
WACC7.74%
2.3 Liquidity
A Current Ratio of 1.43 indicates that 1SXP should not have too much problems paying its short term obligations.
The Current ratio of 1SXP (1.43) is worse than 68.75% of its industry peers.
1SXP has a Quick Ratio of 1.07. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of 1SXP (1.07) is worse than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased strongly by -32.93% in the last year.
The Earnings Per Share has been growing by 14.04% on average over the past years. This is quite good.
The Revenue for 1SXP has decreased by -28.74% in the past year. This is quite bad
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)-32.93%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)-28.74%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%7.95%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.91% on average per year.
The Revenue is expected to grow by 9.19% on average over the next years. This is quite good.
EPS Next Y4.94%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
EPS Next 5Y12.91%
Revenue Next Year5.25%
Revenue Next 2Y8.4%
Revenue Next 3Y9.21%
Revenue Next 5Y9.19%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 27.09, the valuation of 1SXP can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 75.00% of the companies listed in the same industry.
1SXP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.45.
The Price/Forward Earnings ratio is 21.19, which indicates a rather expensive current valuation of 1SXP.
62.50% of the companies in the same industry are more expensive than 1SXP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.90. 1SXP is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.09 | ||
| Fwd PE | 21.19 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1SXP indicates a slightly more expensive valuation: 1SXP is more expensive than 75.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.94 | ||
| EV/EBITDA | 15.78 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1SXP's earnings are expected to grow with 13.40% in the coming years.
PEG (NY)5.48
PEG (5Y)N/A
EPS Next 2Y12.5%
EPS Next 3Y13.4%
5. Dividend
5.1 Amount
With a yearly dividend of 0.57%, 1SXP is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.73, 1SXP pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.42, 1SXP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.57% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.33% of its income as dividend. This is a sustainable payout ratio.
DP16.33%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
FRA:1SXP (7/3/2025, 7:00:00 PM)
26.55
-0.05 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.00B
Analysts76.84
Price Target30.64 (15.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.57% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.47%
Min EPS beat(2)-14.42%
Max EPS beat(2)5.48%
EPS beat(4)2
Avg EPS beat(4)7.72%
Min EPS beat(4)-14.42%
Max EPS beat(4)50.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.78%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)1.75%
Revenue beat(4)2
Avg Revenue beat(4)1.13%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)11.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.73%
PT rev (3m)9.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.09 | ||
| Fwd PE | 21.19 | ||
| P/S | 4.11 | ||
| P/FCF | 59.94 | ||
| P/OCF | 19.38 | ||
| P/B | 4.78 | ||
| P/tB | 4.96 | ||
| EV/EBITDA | 15.78 |
EPS(TTM)0.98
EY3.69%
EPS(NY)1.25
Fwd EY4.72%
FCF(TTM)0.44
FCFY1.67%
OCF(TTM)1.37
OCFY5.16%
SpS6.46
BVpS5.56
TBVpS5.35
PEG (NY)5.48
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.93% | ||
| ROE | 17.64% | ||
| ROCE | 17.43% | ||
| ROIC | 14.25% | ||
| ROICexc | 14.71% | ||
| ROICexgc | 15.16% | ||
| OM | 18.95% | ||
| PM (TTM) | 15.17% | ||
| GM | 32.9% | ||
| FCFM | 6.86% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score4
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.33 | ||
| Debt/EBITDA | 0.32 | ||
| Cap/Depr | 193.54% | ||
| Cap/Sales | 14.35% | ||
| Interest Coverage | 12.84 | ||
| Cash Conversion | 80.44% | ||
| Profit Quality | 45.2% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | N/A |
F-Score4
WACC7.74%
ROIC/WACC1.84
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.93%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next Y4.94%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
EPS Next 5Y12.91%
Revenue 1Y (TTM)-28.74%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%7.95%
Revenue Next Year5.25%
Revenue Next 2Y8.4%
Revenue Next 3Y9.21%
Revenue Next 5Y9.19%
EBIT growth 1Y-27.36%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year39.55%
EBIT Next 3Y25.42%
EBIT Next 5Y19.41%
FCF growth 1Y1205.97%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y24.04%
OCF growth 3Y19.45%
OCF growth 5YN/A